Latest Cisplatin Stories
SCHAUMBURG, Ill., Aug.
INDIANAPOLIS, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company continues to lead the way in advancing lung cancer treatment.
SOMERSET, N.J., June 19 /PRNewswire-FirstCall/ -- Dear Shareholder, I am grateful to have this opportunity to share with you important developments taking place at this critical juncture in our company history.
Promising Preliminary Results on Radiation Sensitization from Phase II Trial May Serve as Additional Registration Direction for OPAXIO ORLANDO, Fla., June 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Daqing Li and colleagues, at the University of Pennsylvania School of Medicine, Philadelphia, have identified in vitro and in mice a way to enhance the anticancer effects of the commonly used platinum-based drug cisplatin.
ORLANDO, Fla., May 31 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer.
INDIANAPOLIS, May 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA(R) (pemetrexed for injection) as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with other than predominantly squamous cell histology in patients whose disease has not progressed...
INDIANAPOLIS, May 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will unveil data from more than 50 studies at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla.
FREDERICK, Md., April 30 /PRNewswire/ -- Royer Animal Health, LLC, a wholly owned subsidiary of Royer Biomedical, Inc., has executed an exclusive distribution agreement with MWI Veterinary, Supply, Inc.
ZURICH, Switzerland, March 20 /PRNewswire/ -- A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients.
- Large; stout; burly.